

Christoph Heesen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1500573/publications.pdf>

Version: 2024-02-01

162
papers

5,945
citations

76294

40
h-index

88593

70
g-index

173
all docs

173
docs citations

173
times ranked

6628
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. <i>Multiple Sclerosis Journal</i> , 2008, 14, 988-991.	1.4	431
2	Exercise in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2017, 16, 848-856.	4.9	316
3	Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 34-39.	0.9	275
4	Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2004, 225, 11-18.	0.3	244
5	Frequent neurocognitive deficits after recovery from mild COVID-19. <i>Brain Communications</i> , 2020, 2, fcaa205.	1.5	236
6	Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 382-390.	1.4	174
7	A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. <i>Annals of Neurology</i> , 2012, 72, 199-210.	2.8	140
8	Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). <i>Multiple Sclerosis Journal</i> , 2001, 7, 119-130.	1.4	138
9	Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 643-650.	1.4	137
10	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
11	Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. <i>Multiple Sclerosis Journal</i> , 2003, 9, 404-410.	1.4	107
12	An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. <i>Lancet Psychiatry</i> , the, 2015, 2, 217-223.	3.7	104
13	Impaired social cognition in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 523-528.	0.9	102
14	Correlates of cognitive dysfunction in multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1148-1155.	2.0	91
15	Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. <i>European Journal of Neurology</i> , 2008, 15, 1345-1352.	1.7	90
16	Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 299, 53-58.	1.1	88
17	Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. <i>Multiple Sclerosis Journal</i> , 2009, 15, 96-104.	1.4	85
18	Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1356-1365.	1.4	85

#	ARTICLE	IF	CITATIONS
19	Stress and hypothalamicâ€“pituitaryâ€“adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosisâ€“A review. <i>Psychoneuroendocrinology</i> , 2007, 32, 604-618.	1.3	83
20	Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1507-1512.	1.4	76
21	MAPPIN'SDM â€“ The Multifocal Approach to Sharing in Shared Decision Making. <i>PLoS ONE</i> , 2012, 7, e34849.	1.1	76
22	Cognitive impairment correlates with hypothalamoâ€“pituitaryâ€“adrenal axis dysregulation in multiple sclerosis. <i>Psychoneuroendocrinology</i> , 2002, 27, 505-517.	1.3	73
23	Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagement. <i>Journal of the Neurological Sciences</i> , 2011, 306, 192-197.	0.3	73
24	Perceptions on the value of bodily functions in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 356-362.	1.0	71
25	Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 970-976.	0.9	69
26	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 681-686.	0.9	66
27	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 411-418.	0.9	63
28	Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging. <i>PLoS ONE</i> , 2016, 11, e0151496.	1.1	59
29	Evidence-based patient information about treatment of multiple sclerosisâ€“A phase one study on comprehension and emotional responses. <i>Patient Education and Counseling</i> , 2006, 62, 56-63.	1.0	57
30	Ecological Validity of Walking Capacity Tests in Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0123822.	1.1	55
31	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e446.	3.1	54
32	Information provision for people with multiple sclerosis. <i>The Cochrane Library</i> , 2014, , CD008757.	1.5	53
33	Hypothalamoâ€“pituitaryâ€“adrenal axis activity predicts disease progression in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 165, 186-191.	1.1	52
34	Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale. <i>PLoS ONE</i> , 2013, 8, e66127.	1.1	52
35	Childhood Trauma in Multiple Sclerosis. <i>Psychosomatic Medicine</i> , 2012, 74, 312-318.	1.3	49
36	Patient education for people with multiple sclerosis-associated fatigue: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0173025.	1.1	49

#	ARTICLE	IF	CITATIONS
37	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial study protocol. <i>BMJ Open</i> , 2016, 6, e010956.	0.8	46
38	Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1303-1308.	1.4	46
39	Relapse in multiple sclerosis. <i>BMJ</i> , 2015, 350, h1765-h1765.	3.0	44
40	Comparison of patient-reported outcome measures in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, 114-121.	1.0	43
41	Patient autonomy in multiple sclerosis – Possible goals and assessment strategies. <i>Journal of the Neurological Sciences</i> , 2013, 331, 2-9.	0.3	41
42	Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue. <i>Multiple Sclerosis Journal</i> , 2005, 11, 51-57.	1.4	40
43	Accuracy of diagnostic tests in multiple sclerosis - a systematic review. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 151-164.	1.0	37
44	Dynamic Development of Glucocorticoid Resistance during Autoimmune Neuroinflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1402-E1410.	1.8	37
45	Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program. <i>PLoS ONE</i> , 2016, 11, e0165246.	1.1	37
46	Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review. <i>PLoS ONE</i> , 2014, 9, e92761.	1.1	35
47	Increased Perfusion in Normal Appearing White Matter in High Inflammatory Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0119356.	1.1	35
48	Stress regulation in multiple sclerosis – current issues and concepts. <i>Multiple Sclerosis Journal</i> , 2007, 13, 143-148.	1.4	34
49	T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2015, 10, e0144693.	1.1	34
50	Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires. <i>Brain and Behavior</i> , 2015, 5, e00365.	1.0	32
51	Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1618-1632.	1.4	32
52	Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1977-1993.	1.4	32
53	Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. <i>PLoS ONE</i> , 2015, 10, e0127734.	1.1	31
54	Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) – Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation. <i>International Journal of Nursing Studies</i> , 2018, 78, 26-36.	2.5	30

#	ARTICLE	IF	CITATIONS
55	Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial. <i>PeerJ</i> , 2018, 6, e6037.	0.9	28
56	Information provision for people with multiple sclerosis. <i>The Cochrane Library</i> , 2018, 2018, CD008757.	1.5	27
57	Managing Neuropsychological Impairment in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 130-137.	0.4	26
58	Behavioral interventions in multiple sclerosis: a biopsychosocial perspective. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1089-1100.	1.4	25
59	A <i>W</i> -based tool for personalized prediction of long-term disease course in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1107-1109.	1.7	24
60	Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability. <i>NeuroImage: Clinical</i> , 2020, 25, 102177.	1.4	24
61	Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2015, 16, 106.	0.7	23
62	Reduced rich-club connectivity is related to disability in primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e375.	3.1	23
63	A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 330-338.	0.9	23
64	Implementation of a patient education program on multiple sclerosis relapse management. <i>Patient Education and Counseling</i> , 2012, 86, 91-97.	1.0	22
65	Noise robust spatially regularized myelin water fraction mapping with the intrinsic $B_{1\text{-error}}$ correction based on the linearized version of the extended phase graph model. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 800-817.	1.9	22
66	Training doctors briefly and in situ to involve their patients in making medical decisions—Preliminary testing of a newly developed module. <i>Health Expectations</i> , 2017, 20, 1254-1263.	1.1	22
67	T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017, 38, 264-269.	1.2	22
68	Placebo Cohorts in Phase-3 MS Treatment Trials — Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data. <i>PLoS ONE</i> , 2012, 7, e50347.	1.1	22
69	Suspected multiple sclerosis — what to do? Evaluation of a patient information leaflet. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1103-1112.	1.4	21
70	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	1.1	21
71	Responsiveness of patient-based and external rating scales in multiple sclerosis: Head-to-head comparison in three clinical settings. <i>Journal of the Neurological Sciences</i> , 2010, 290, 102-106.	0.3	20
72	Biological outcome measurements for behavioral interventions in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 217-229.	1.5	20

#	ARTICLE	IF	CITATIONS
73	Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions. PLoS ONE, 2015, 10, e0138364.	1.1	19
74	Applying the theory of planned behaviour to multiple sclerosis patients'™ decisions on disease modifying therapy " questionnaire concept and validation. BMC Medical Informatics and Decision Making, 2012, 12, 60.	1.5	18
75	Magnetic Resonance Imaging in Multiple Sclerosis " Patients' Experiences, Information Interests and Responses to an Education Programme. PLoS ONE, 2014, 9, e113252.	1.1	18
76	Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 963-969.	1.2	18
77	Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e325.	3.1	18
78	Risk knowledge of people with relapsing-remitting multiple sclerosis " Results of an international survey. PLoS ONE, 2018, 13, e0208004.	1.1	18
79	Effect of informed consent on patient characteristics in a stroke thrombolysis trial. Neurology, 2017, 89, 1400-1407.	1.5	17
80	A new graphical format to communicate treatment effects to patients" A web-based randomized controlled trial. Health Expectations, 2017, 20, 797-804.	1.1	16
81	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	0.8	16
82	Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period. PLoS ONE, 2017, 12, e0172923.	1.1	16
83	Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?. PLoS ONE, 2017, 12, e0174858.	1.1	16
84	Possible determinants of long-term adherence to physical activity in multiple sclerosis" theory-based development of a comprehensive questionnaire and results from a German survey study. Disability and Rehabilitation, 2021, 43, 3175-3188.	0.9	16
85	Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging. PLoS ONE, 2021, 16, e0245844.	1.1	16
86	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
87	Long-term physical activity in people with multiple sclerosis: exploring expert views on facilitators and barriers. Disability and Rehabilitation, 2020, 42, 3059-3071.	0.9	15
88	Fatigue in Multiple Sclerosis Is Associated With Childhood Adversities. Frontiers in Psychiatry, 2020, 11, 811.	1.3	15
89	Patient autonomy in dentistry: demonstrating the role for shared decision making. BMC Medical Informatics and Decision Making, 2020, 20, 318.	1.5	15
90	Smartphone Accelerometry: A Smart and Reliable Measurement of Real-Life Physical Activity in Multiple Sclerosis and Healthy Individuals. Frontiers in Neurology, 2020, 11, 688.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 129-137.	0.4	15
92	The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 127-133.	1.8	14
93	Recall of health-related quality of life: how does memory affect the SF-6D in patients with psoriasis or multiple sclerosis? A prospective observational study in Germany. <i>BMJ Open</i> , 2019, 9, e032859.	0.8	14
94	Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting. <i>PeerJ</i> , 2016, 4, e2442.	0.9	14
95	Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool. <i>PLoS ONE</i> , 2013, 8, e59042.	1.1	13
96	Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes. <i>Journal of the Neurological Sciences</i> , 2016, 368, 318-325.	0.3	13
97	Patient education programme on immunotherapy in multiple sclerosis (PEPIMS): a controlled rater-blinded study. <i>Clinical Rehabilitation</i> , 2017, 31, 250-261.	1.0	13
98	Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e621.	3.1	13
99	Feasibility of a smartphone app to enhance physical activity in progressive MS: a pilot randomized controlled pilot trial over three months. <i>PeerJ</i> , 2020, 8, e9303.	0.9	13
100	Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. <i>Multiple Sclerosis Journal</i> , 2013, 19, 920-925.	1.4	12
101	A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients. <i>Journal of the Neurological Sciences</i> , 2014, 346, 99-106.	0.3	12
102	Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 18-32.	1.0	12
103	Impairment and restrictions in possibly benign multiple sclerosis. <i>Brain and Behavior</i> , 2019, 9, e01259.	1.0	12
104	Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?. <i>PLoS ONE</i> , 2015, 10, e0116559.	1.1	11
105	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e728.	3.1	11
106	Current and Long-Term Physical Activity Among Adults with Multiple Sclerosis in the United States: COM-B Variables as Explanatory Factors. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 561-574.	0.8	11
107	Subjective and objective knowledge and decisional role preferences in cerebrovascular patients compared to controls. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1453-1460.	0.8	10
108	Low clinical conversion rate in clinically isolated syndrome patients â€“ diagnostic benefit of McDonald 2010 criteria?. <i>European Journal of Neurology</i> , 2018, 25, 247.	1.7	10

#	ARTICLE	IF	CITATIONS
109	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	1.9	10
110	Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 255.	1.0	10
111	Chronic T2 Lesions in Multiple Sclerosis are Heterogeneous Regarding Phase MR Imaging. <i>Clinical Neuroradiology</i> , 2016, 26, 457-464.	1.0	9
112	What should a person with relapsing-remitting multiple sclerosis know? â€œ Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0). <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 186-195.	0.9	9
113	Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. <i>PLoS ONE</i> , 2020, 15, e0228587.	1.1	9
114	â€œœ Will Respect the Autonomy of My Patientâ€œ. <i>International Journal of MS Care</i> , 2020, 22, 285-293.	0.4	9
115	Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)â€œ study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 139.	0.7	8
116	Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1666.	1.8	7
117	Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial. <i>BMC Medical Informatics and Decision Making</i> , 2016, 16, 122.	1.5	7
118	Ruxolitinib treatment in a patient with neuromyelitis optica: A case report. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e328.	3.1	7
119	Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample. <i>Patient Education and Counseling</i> , 2018, 101, 74-78.	1.0	7
120	Patients experiences with multiple sclerosis disease-modifying therapies in daily life â€œ a qualitative interview study. <i>BMC Health Services Research</i> , 2021, 21, 1141.	0.9	7
121	T1 Relaxation Times in the Cortex and Thalamus Are Associated With Working Memory and Information Processing Speed in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 789812.	1.1	7
122	Changes of Motivational Variables in Patients with Multiple Sclerosis in an Exercise Intervention: Associations between Physical Performance and Motivational Determinants. <i>Behavioural Neurology</i> , 2015, 2015, 1-7.	1.1	6
123	Medication beliefs in first-line and second-line treated multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102144.	0.9	6
124	Is multiple sclerosis progression associated with the HLA-DR15 haplotype?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989461.	0.5	5
125	Prognostic information for people with MS: Impossible or inevitable?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 771-773.	1.4	5
126	Impact of a multimedia website with patient experiences of multiple sclerosis (PExMS) on immunotherapy decision-making: study protocol for a pilot randomised controlled trial in a mixed-methods design. <i>Pilot and Feasibility Studies</i> , 2021, 7, 16.	0.5	5

#	ARTICLE	IF	CITATIONS
127	Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). <i>BMJ Open</i> , 2021, 11, e041720.	0.8	5
128	How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. <i>Quality of Life Research</i> , 2021, 30, 2081-2096.	1.5	5
129	Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)â€”Results of a Pilot Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 644533.	1.1	5
130	Managing neuropsychological impairment in multiple sclerosis â€” Controlled study on a standardized metacognitive intervention (MaTiMS). <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103687.	0.9	5
131	Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function. <i>European Journal of Neurology</i> , 2022, 29, 1741-1752.	1.7	5
132	Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1387-1388.	1.4	4
133	<p>Reasons for delayed admission after stroke: results of a qualitative and quantitative survey</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 739-747.	0.8	4
134	Spectrally fat-suppressed coronal 2D TSE sequences may be more sensitive than 2D STIR for the detection of hyperintense optic nerve lesions. <i>European Radiology</i> , 2019, 29, 6266-6274.	2.3	4
135	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. <i>Scientific Reports</i> , 2020, 10, 8776.	1.6	4
136	Benefit evaluation in multiple sclerosis relapse treatment from the patientsâ€™ perspective â€” Development and validation of a new questionnaire. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 256-261.	0.9	3
137	Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1442-1450.	1.4	3
138	Developing a fall prevention program: what are the views and opinions of people with multiple sclerosis?. <i>Disability and Rehabilitation</i> , 2021, 43, 1065-1073.	0.9	3
139	Perceived and Objective Attentional Deficits in Multiple Sclerosis. <i>Zeitschrift FÃ¼r Neuropsychologie = Journal of Neuropsychology</i> , 2015, 26, 171-178.	0.2	3
140	Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS): Development and Piloting of an Online Education Program About Magnetic Resonance Imaging for People With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 856240.	1.1	3
141	Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 133.	1.1	2
142	Quality of Stroke Patient Information Applied in Randomized Controlled Trialsâ€”Literature Review. <i>Frontiers in Neurology</i> , 2020, 11, 526515.	1.1	2
143	Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMSâ€”understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. <i>Trials</i> , 2020, 21, 1008.	0.7	2
144	Decision-making about corticosteroids in relapses of multiple sclerosis â€” development of a questionnaire based on the theory of planned behaviour. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103182.	0.9	2

#	ARTICLE	IF	CITATIONS
145	Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 57, 103434.	0.9	2
146	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. <i>JMIR Human Factors</i> , 2022, 9, e26825.	1.0	2
147	Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No. <i>Multiple Sclerosis Journal</i> , 2022, 28, 861-862.	1.4	2
148	Personality and its association with self-management in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103752.	0.9	2
149	Development and evaluation of a website with patients experiences of multiple sclerosis: a mixed methods study. <i>BMC Neurology</i> , 2022, 22, 146.	0.8	2
150	Percept: A prospective multicenter observational study on benefit/risk perception of natalizumab in neurologists and their patients in Germany. <i>Journal of the Neurological Sciences</i> , 2013, 333, e379.	0.3	1
151	Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity. <i>Human Brain Mapping</i> , 2021, 42, 3379-3395.	1.9	1
152	Evaluation of an interactive web-based programme on relapse management for people with multiple sclerosis (POWER@MS2): study protocol for a process evaluation accompanying a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e046874.	0.8	1
153	Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103728.	0.9	1
154	The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life. <i>International Journal of MS Care</i> , 2022, 24, 147-153.	0.4	1
155	German guideline for diagnosis and treatment of multiple sclerosis – a survey focusing neurologists in daily practise. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103828.	0.9	1
156	The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) – critical review facing the 20 anniversary. <i>Multiple Sclerosis and Related Disorders</i> , 2022, , 103885.	0.9	1
157	Comprehension of confidence intervals in audio-visual patient information materials for people with multiple sclerosis (COCO-MS): A web-based randomised controlled, parallel group trial. <i>Patient Education and Counseling</i> , 2021, 104, 1132-1139.	1.0	0
158	Guest Editorial. <i>International Journal of MS Care</i> , 2020, 22, xii-xiii.	0.4	0
159	Title is missing!. , 2020, 15, e0228587.		0
160	Title is missing!. , 2020, 15, e0228587.		0
161	Title is missing!. , 2020, 15, e0228587.		0
162	Title is missing!. , 2020, 15, e0228587.		0